the authorities to the Company expires March 31, 2026 and provide a concessionary tax rate of
5
% to earnings in excess of the base income threshold. As a result of the incentive, the Company received an aggregate tax benefit of $
21
million, $
9
million and $
2
million during the year ended December 31, 2024, 2023 and 2022, respectively.
The Company had no material uncertain income tax positions for the years ended December 31, 2024 and 2023. The Company's accounting policy is to recognize interest and penalties related to uncertain tax positions as a component of income tax expense. In the years ended December 31, 2024 and 2023, there was no material interest or penalties related to uncertain tax positions.
The Company remains subject to audit by the relevant tax authorities for the years ended 2017 through 2024.
Investment tax credits, which are earned as a result of qualifying research and development expenditures, are recognized and applied to reduce income tax expense in the year in which the expenditures are made and their realization is reasonably assured.
As of December 31, 2024 and 2023, the Company had Canadian unused non-capital tax losses of approximately $
5
million and $
117
million, respectively. As of December 31, 2024 and 2023, the Company had U.S. federal unused non-capital tax losses of approximately $
306
million and $
383
million, respectively. In addition, as of December 31, 2024 and 2023, the Company had unused non-capital tax losses in various U.S. states of approximately $
339
million and $
1.5
billion, respectively. As of December 31, 2024, $
272
million and $
6
million of the federal and state non-capital tax losses, respectively, have no expiry. The remaining unused federal and state non-capital tax losses of $
34
million and $
333
million, respectively, will begin to expire starting in 2031. As of December 31, 2024, the Company also has $
761
million of capital losses in Canada that do not expire as well as $
1.7
billion of capital losses in the U.S. that expires in 2028. In addition, as of December 31, 2024 and 2023, the Company had an undeducted Canadian research and development expenditure balance totaling $
nil
and $
226
million, respectively. As of December 31, 2024 and 2023, the Company had Canadian and U.S. federal and state tax credits of $
33
million and $
104
million, respectively. The unused U.S. federal tax credits will begin to expire in 2042 and the unused U.S. state research and development credits will begin to expire starting in 2029. The unused Canadian investment tax credits will begin to expire starting in 2043.
114
Table of Contents
22.
Net Income (Loss) per Share
The Company applies the two-class method to calculate its basic and diluted net loss per share as Class A subordinate voting shares and Class B restricted voting shares are participating securities with equal participation rights and are entitled to receive dividends on a share for share basis. The Company uses the treasury stock method